Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers
Posted innews OB/GYN & Women's Health Oncology

Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers

This phase 1/2 study evaluates farletuzumab ecteribulin, a folate receptor alpha-targeting ADC, showing that fractionated dosing reduces interstitial lung disease risk and demonstrates preliminary antitumor activity in advanced ovarian, endometrial, triple-negative breast, and lung cancers.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
Posted innews Oncology

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminating the need for cyclophosphamide pretreatment.